Health Technology Assessment in Pharma: A Review of Major Decisions

Report Scope:

The current report provides details about HTA processes in countries such as U.S., Canada and U.K. This report highlights information and insights on the molecules which were recently approved in terms of regulatory and reimbursement decisions. The report includes policies, country-specific HTA activities, drug overviews, mechanisms of action, disease backgrounds, clinical evidence on safety and efficacy, regulatory scenarios, and HTA evaluation details.

Report Includes:

- 45 tables
- A detailed outlook on the HTA process and its approvals in major pharma industries
- Insights into the recent HTA submissions to HTA agencies by top pharmaceutical manufacturers
- Discussion on how HTA helps in the development of safe, and effective health policies, thereby benefitting both patient and health care providers
- Information about the medical, social, economic and ethical issues related to the use of a health technology
- Company profiles of market-leading players, including Janssen Pharmaceuticals Inc., Merck & Co. Inc., AstraZeneca PLC, Eli Lilly and Co., and Hofmann-La Roche Inc.

Chapter 1 Introduction
Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Analysts Credentials
BCC Custom Research
Related BCC Research Reports
Chapter 2 Introduction to Health Technology Assessment
Introduction
Origins of Technology Assessment
Fundamental Concepts
Health Technology
Health Technology Categories
Purpose or Application
Stage of Diffusion
Health Technology Assessment
Purposes of HTA
Chapter 3 Pharmaceutical Industrys Perspective on HTA
HTA and Efficiency
HTA: A Cost Driver
Implementation Barriers
Chapter 4 Overview of Global HTA Organizations
HTA in Europe
United Kingdom (England and Wales)
Scotland
Germany
France
Italy
HTA in North America
U.S.
Canada
HTA in the Asia-Pacific Region
Japan
China
Australia
Chapter 5 Daratumumab (Darzalex)
Overview of Daratumumab
Scientific Summary
Pharmacodynamics and Mechanism of Action
Clinical Trials to Assess Safety and Efficacy
Disease Background
Multiple Myeloma: Disease Overview
Staging and Prognosis
Signs and Symptoms
Regulatory Milestones
Technology Assessment Decisions
NICE U.K.
SMC Scotland
Haute de sant (HAS) France
CADTH (pCODR) Canada
Company Profile
JANSSEN PHARMACEUTICALS INC.
Chapter 6 Tildrakizumab (Ilumya)
Overview of Tildrakizumab
Scientific Summary
Pharmacodynamics and Mechanism of Action
Clinical Trials to Assess Safety and Efficacy
Disease Background
Psoriasis: Disease Overview
Regulatory Milestones
Technology Assessment Decisions
NICE U.K.
SMC Scotland
Company Profile
MERCK AND CO. INC.
Chapter 7 Durvalumab (Imfinzi)
Overview of Durvalumab
Scientific Summary
Pharmacodynamics and Mechanism of Action
Clinical Trials to Assess Safety and Efficacy
Disease Background
Non-small Cell Lung Cancer: Disease Overview
Regulatory Milestones
Technology Assessment Decisions
NICE U.K.
SMC Scotland
CADTH (pCODR) Canada
HAS France
Company Profile
ASTRAZENECA PLC
Chapter 8 Abemaciclib (Verzenio)
Overview of Abemaciclib
Scientific Summary
Pharmacodynamics and Mechanism of Action
Clinical Trials to Assess Safety and Efficacy
Disease Background
Breast Cancer: Disease Overview
Regulatory Milestones
Technology Assessment Decisions
NICE U.K.
SMC Scotland
CADTH (pCODR) Canada
HAS France
Company Profile
ELI LILLY AND CO.
Chapter 9 Ocrelizumab (Ocrevus)
Overview of Ocrelizumab
Scientific Summary
Pharmacodynamics and Mechanism of Action
Clinical Trials to Assess Safety and Efficacy
Disease Background
Multiple Sclerosis: Disease Overview
Regulatory Milestones
Technology Assessment Decisions
NICE U.K.
SMC Scotland
CADTH Canada
HAS France
Company Profile
HOFFMANN-LA ROCHE INC.
Chapter 10 Conclusion

List Of Tables


Table 1 : Types of Health Technologies, by Category
Table 2 : Types of Health Technologies, by Application
Table 3 : Types of Health Technologies, by Stage of Diffusion
Table 4 : National Healthcare Spending in Germany, by Sector/ Services, 2015-2017
Table 5 : Key Organizations Involved in the Reimbursement of Pharmaceuticals and Medical Devices in France
Table 6 : Key Organizations Involved in the Reimbursement of Pharmaceuticals in the U.S.
Table 7 : Public Health Insurance Programs in the U.S.
Table 8 : National Healthcare Expenditures in Canada, 2010-2019
Table 9 : National Healthcare Expenditures of Canada, by Sector/Service, 2017
Table 10 : Trends in Japanese Healthcare Expenditures, 1995-2016
Table 11 : National Healthcare Expenditures in Japan, by Sector/Service, 1995-2014
Table 12 : Distribution Shares of Healthcare Spending on Pharmaceuticals in China, 2017
Table 13 : Trends in the Number of Medicines Included in Previous National Essential Medicines Lists, 1982-2009
Table 14 : National Health Expenditures in Australia, by Sector/Service, 2017-2018
Table 15 : Key U.S. Clinical Trials on Daratumumab
Table 16 : Multiple Myeloma International Staging System
Table 17 : Regulatory Milestones of Daratumumab, 2013-2015
Table 18 : NICE Technology Assessment of Daratumumab
Table 19 : SMC Technology Assessment of Daratumumab
Table 20 : HAS Technology Assessment of Daratumumab
Table 21 : CADTH-pCODR Technology Assessment of Daratumumab
Table 22 : Key U.S. Clinical Trials on Tildrakizumab
Table 23 : Tildrakizumab Regulatory Milestones
Table 24 : NICE Technology Assessment of Tildrakizumab
Table 25 : SMC Technology Assessment of Tildrakizumab
Table 26 : Key U.S. Clinical Trials on Tildrakizumab
Table 27 : Regulatory Milestones of Durvalumab
Table 28 : NICE Technology Assessment of Durvalumab
Table 29 : SMC Technology Assessment of Durvalumab
Table 30 : CADTH-pCODR Technology Assessment of Durvalumab
Table 31 : HAS Technology Assessment of Durvalumab
Table 32 : Key U.S. Clinical Trials on Abemaciclib
Table 33 : Regulatory Milestones of Abemaciclib
Table 34 : NICE Technology Assessment of Abemaciclib
Table 35 : SMC Technology Assessment of Abemaciclib
Table 36 : CADTH-pCODR Technology Assessment of Abemaciclib
Table 37 : HAS Technology Assessment of Abemaciclib
Table 38 : Key U.S. Clinical Trials on Ocrelizumab
Table 39 : Incidence and Prevalence of Multiple Sclerosis Cases, by Country, 2016
Table 40 : Regulatory Milestones of Ocrelizumab
Table 41 : NICE Technology Assessment of Ocrelizumab
Table 42 : SMC Technology Assessment of Ocrelizumab
Table 43 : CADTH Technology Assessment of Ocrelizumab
Table 44 : HAS Technology Assessment of Ocrelizumab

List Of Figures


Figure 1 : Shares of Healthcare Expenditures in the U.K., by Sector, 2017
Figure 2 : IQWiG Technology Assessment Process
Figure 3 : IQWiG Conclusions on the Benefits of Assessments
Figure 4 : Shares of National Healthcare Expenditures in the U.S., by Sector, 2018
Figure 5 : Schematic of the Reimbursement Process in the U.S.
Figure 6 : Features of the Asia-Pacific Market
Figure 7 : Shares of Drugs Listed in the National Formulary of China, by Therapeutic Area, 2017
Figure 8 : Management of Advanced Non-small Cell Lung Cancer and Expected Outcomes

2022 Whats Next for Animal Health Market?--Emerging Trends, Forecasts, Latest Technologies, Competitive SWOT Analysis

- Will the industry consolidate, decentralize, or undergo a bimodal transformation- How will the current trends affect the major market segments- Which companies will enter the market and which will

USD 4850 View Report

2022 Virbac Half-Year Review and Outlook--Strategic SWOT Analysis, Performance, Capabilities, Goals and Strategies in the Global Animal Health Industry

This report is part of the LeadingMarketResearch.com Competitive Analysis Series, which includes assessments of more than 1,000 companies worldwide.The report provides significant competitor information, analysis and insight critical to the

USD 850 View Report

2020 Cancer Diagnostics Market: US, Europe, Japan--Supplier Shares by Test, Country Volume and Sales Forecasts, Profiles of Leading Competitors, Emerging Tumor Markers, Technology Assessment, Instrumentation Review

This new report provides analysis of the global cancer diagnostics market, including emerging tests, Technologies, instrumentation, sales forecasts by country, and strategic profiles of leading suppliers. The report presents:Estimated

USD 7500 View Report

Coagulation Testing Market, 2019-2023: Emerging Tests, Technology Assessment, Instrumentation Review, Sales Forecasts by Country, and Strategic Profiles of Leading Suppliers

This new 302-page report provides analysis of the global coagulation testing market, including emerging tests, technologies, instrumentation, sales forecasts by country, and strategic profiles of leading suppliers.  The report

USD 7500 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available

 

 

FAQs

Yes, you will receive a sample copy of the market research report from the sales team when you put a query to us. The sample report is free and offers a brief view of the report and information on data available before you purchase the full-fledged report. Also, we will provide a demo sample for any oncoming study.

Select the report you wish to purchase and proceed to buy it by making an online payment. We use a secured gateway for payment transfers and do not share your financial information with any unconcerned third party.

The report will be delivered in spreadsheet and PDF format. In some cases, PPT formats could be available as well.

After confirmation of the payment, you will receive the electronic format of the report at your registered email address in (mention the timeline for the delivery). If you buy a report over a holiday or weekend, we will process the request the next working day.

Market studies and reports already contain important data and are ready for distribution to the purchaser. However, if there is any particular query, addition, or customization you require, then contact us on our email id or phone. We will look to accommodate your request and see what can be done at the earliest. The research team will design the report accordingly and discuss the solutions beforehand with you.

The price of the customized report will be conveyed to you by our team after we agree on the deliverable. A delivery timeline will be set so that you get the report within the expected date. Any requests for customizations after selling the report will be handled by a separate department and the prices for the same mentioned upfront.

While usually such a request is not accommodated as any market research report is wholesome and the cost of the report is for overall contents, in special cases, we may be able to sell select segments of the report based on your requirements.

Our team will love to support academicians, start-ups, students, and others with consulting and research. Thus, our pricing plan is based on keeping these interests in mind and is already affordable. However, we may have discounts available for particular customer types and reports. So, contact us for more information.

We have consumer-centric reports and offer several facilities before selling. You will get a free review and sample report, talk to our customer care team for any additions to be done and meet special requirements, and interact with our analysts for deeper understanding.

Yes, you will get an invoice for the purchase you made. The invoice will be sent to you electronically on your registered email id.

We have a vast database of market reports and studies and there are a few which may not have been uploaded yet. If you are unable to find the one you want, then get in touch with our sales team by phone or email and we will connect with you for assistance.

Not every study is the same. Thus, the update for reports will depend on the ongoing research and changes if any to be incorporated in the document or not.

The market research reports are constructed keeping in mind the industry trends, nature of the study, and required inputs. But if you want something more than what is stated in the report, we can help you out with further research if possible. Contact us right away, and we will do the needful to aid you.

Once the payment is done, it is non-refundable because as per the standard policy, the utility of the reports is based on knowledge sharing, and thus, a refund is not possible to make after we have issued you obtain the study. To avoid the hassle, we have a detailed view of the report and its ideas through a sample report.

If the payment fails then be assured that you shall receive the money back to the source payment mode from the payment gateway. Aarkstore is not responsible for any loss of payment in the process.

Yes, we can provide a report or segment related to a particular region or geography if we have that feature available for the document.

Yes, we are here to solve any queries you may have for the report from our analyst till a given timeframe. To understand more about this, get in touch with us.